243 related articles for article (PubMed ID: 12478089)
1. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.
Brenner B; Turner D; Oliveira M; Moisi D; Detorio M; Carobene M; Marlink RG; Schapiro J; Roger M; Wainberg MA
AIDS; 2003 Jan; 17(1):F1-5. PubMed ID: 12478089
[TBL] [Abstract][Full Text] [Related]
2. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.
Loemba H; Brenner B; Parniak MA; Ma'ayan S; Spira B; Moisi D; Oliveira M; Detorio M; Wainberg MA
Antimicrob Agents Chemother; 2002 Jul; 46(7):2087-94. PubMed ID: 12069959
[TBL] [Abstract][Full Text] [Related]
3. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
4. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
[TBL] [Abstract][Full Text] [Related]
6. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
Whitcomb JM; Huang W; Limoli K; Paxinos E; Wrin T; Skowron G; Deeks SG; Bates M; Hellmann NS; Petropoulos CJ
AIDS; 2002 Oct; 16(15):F41-7. PubMed ID: 12370521
[TBL] [Abstract][Full Text] [Related]
7. Genotypic evaluation of etravirine sensitivity of clinical human immunodeficiency virus type 1 (HIV-1) isolates carrying resistance mutations to nevirapine and efavirenz.
Oumar AA; Jnaoui K; Kabamba-Mukadi B; Yombi JC; Vandercam B; Goubau P; Ruelle J
Acta Clin Belg; 2010; 65(4):242-4. PubMed ID: 20954462
[TBL] [Abstract][Full Text] [Related]
8. Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors.
Clark SA; Shulman NS; Bosch RJ; Mellors JW
AIDS; 2006 Apr; 20(7):981-4. PubMed ID: 16603849
[TBL] [Abstract][Full Text] [Related]
9. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C.
Grossman Z; Istomin V; Averbuch D; Lorber M; Risenberg K; Levi I; Chowers M; Burke M; Bar Yaacov N; Schapiro JM;
AIDS; 2004 Apr; 18(6):909-15. PubMed ID: 15060438
[TBL] [Abstract][Full Text] [Related]
10. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
[TBL] [Abstract][Full Text] [Related]
11. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
[TBL] [Abstract][Full Text] [Related]
12. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
Casado JL; Hertogs K; Ruiz L; Dronda F; Van Cauwenberge A; Arnó A; Garcia-Arata I; Bloor S; Bonjoch A; Blazquez J; Clotet B; Larder B
AIDS; 2000 Jan; 14(2):F1-7. PubMed ID: 10708276
[TBL] [Abstract][Full Text] [Related]
13. Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.
Lai MT; Lu M; Felock PJ; Hrin RC; Wang YJ; Yan Y; Munshi S; McGaughey GB; Tynebor RM; Tucker TJ; Williams TM; Grobler JA; Hazuda DJ; McKenna PM; Miller MD
Antimicrob Agents Chemother; 2010 Nov; 54(11):4812-24. PubMed ID: 20805392
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C.
Quan Y; Brenner BG; Marlink RG; Essex M; Kurimura T; Wainberg MA
AIDS Res Hum Retroviruses; 2003 Sep; 19(9):743-53. PubMed ID: 14585205
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations.
Eshleman SH; Jones D; Galovich J; Paxinos EE; Petropoulos CJ; Jackson JB; Parkin N
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):289-93. PubMed ID: 16545016
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.
Shulman N; Zolopa AR; Passaro D; Shafer RW; Huang W; Katzenstein D; Israelski DM; Hellmann N; Petropoulos C; Whitcomb J
AIDS; 2001 Jun; 15(9):1125-32. PubMed ID: 11416714
[TBL] [Abstract][Full Text] [Related]
17. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.
Feng M; Wang D; Grobler JA; Hazuda DJ; Miller MD; Lai MT
Antimicrob Agents Chemother; 2015 Jan; 59(1):590-8. PubMed ID: 25385110
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance.
Loemba H; Brenner B; Parniak MA; Ma'ayan S; Spira B; Moisi D; Oliveira M; Detorio M; Essex M; Wainberg MA
Antiviral Res; 2002 Nov; 56(2):129-42. PubMed ID: 12367719
[TBL] [Abstract][Full Text] [Related]
19. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
Anta L; Llibre JM; Poveda E; Blanco JL; Alvarez M; Pérez-Elías MJ; Aguilera A; Caballero E; Soriano V; de Mendoza C;
AIDS; 2013 Jan; 27(1):81-5. PubMed ID: 22842995
[TBL] [Abstract][Full Text] [Related]
20. Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
Ochoa de Echagüen A; Arnedo M; Xercavins M; Martinez E; Rosón B; Ribera E; Domingo P; González A; Riera M; Llibre JM; Gatell JM; Dalmau D;
AIDS; 2005 Sep; 19(13):1385-91. PubMed ID: 16103769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]